Get the Stockscreener App
0.9674
2.09%
0.0198
Biocardia Inc stock is traded at $0.9674, with a volume of 883.00K.
It is up +2.09% in the last 24 hours and up +7.48% over the past month.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
See More
Previous Close:
$0.9476
Open:
$0.99
24h Volume:
883.00K
Relative Volume:
0.34
Market Cap:
$14.40M
Revenue:
$3,000
Net Income/Loss:
$-7.78M
P/E Ratio:
-0.935
EPS:
-1.0346
Net Cash Flow:
$-7.49M
1W Performance:
+21.67%
1M Performance:
+7.48%
6M Performance:
-24.42%
1Y Performance:
-54.37%
1-Day Range:
$0.921
$1.03
1-Week Range:
$0.795
$1.03
52-Week Range:
$0.7765
$2.45
Biocardia Inc Stock (BCDA) Company Profile
Name
Biocardia Inc
Sector
Industry
Phone
650-226-0123
Address
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.38 | 3.16B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.54 | 425.01M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.26 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.909 | 269.09M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.61 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-21 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Stock (BCDA) Latest News
BioCardia (BCDA) Shares Strategic Business Update Following Capi - GuruFocus
BioCardia's High-Stakes Gambit: A Japan-First Strategy for Heart Therapy - BriefGlance
BioCardia plans Japan regulatory submission for heart therapy By Investing.com - Investing.com South Africa
BioCardia plans Japan regulatory submission for heart therapy - Investing.com
BioCardia targets Japan PMDA submission for CardiAMP, advances U.S. trial and partnership opportunities - TradingView
BioCardia (NASDAQ: BCDA) details Japan approval push and 2026 catalysts - Stock Titan
BioCardia Inc (BCDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioCardia Inc (BCDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioCardia Inc (BCDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioCardia Inc (BCDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioCardia Inc (BCDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioCardia Inc (BCDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioCardia Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
BioCardia (NASDAQ: BCDA) raises $4.9M and updates Nasdaq listing compliance - Stock Titan
BioCardia shares rally after FDA supports regulatory path for heart failure therapy (BCDA) - MSN
BCDA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
BioCardia CEO Peter Altman buys $4,250 in company stock - Investing.com
BioCardia (BCDA) CEO Peter Altman adds 5,000 shares in open-market buy - Stock Titan
Why did BCDA stock surge more than 50% today? - MSN
BioCardia's $4.4M Lifeline: Fuel for Japan, But For How Long? - BriefGlance
Biocardia raises $4.5 million through share sale By Investing.com - Investing.com Nigeria
BioCardia Announces $4.4 Million Financing to Extend Cash Runway Into 2027 and Support Japan PMA Submission 9 - Minichart
Biocardia raises $4.5 million through share sale - Investing.com
BioCardia, Inc. Raises $4.48 Million to Extend Cash Runway into 2027 Ahead of PMDA Submission - Quiver Quantitative
BioCardia Announces $4.4 Million Financing - The Manila Times
BioCardia sells 3.51M shares for $4.49M to extend cash runway into early 2027 - TradingView
BioCardia (NASDAQ: BCDA) extends cash runway with $4.4M equity raise - Stock Titan
BCDA Stock Surges As FDA Softens Trial Requirements For CardiAMP - timothysykes.com
BioCardia Company Profile & Introduction - Moomoo
BCDA Surges As BioCardia Wins Key FDA Trial Backing - StocksToTrade
Why Is BioCardia Stock Gaining Friday? - Sahm
BCDA Surges As BioCardia Wins FDA PMA Pathway Nod - timothysykes.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
$BioCardia (BCDA.US)$ all in all..got a good trade..big profits..but thats all for now..gl all - Moomoo
BioCardia (BCDA) Advances CardiAMP Cell Therapy Approval Process - GuruFocus
BioCardia Jumps After FDA Feedback Seen Positive for CardiAMP Approval - TechStock²
BioCardia jumps after FDA minutes clarify PMA path for CardiAMP HF II trial - Quiver Quantitative
$BioCardia (BCDA.US)$ 🚀🚀🚀 - Moomoo
BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA) - Yahoo Finance
BioCardia’s CardiAMP HF II Clinical Trial May Support FDA Premarket Approval for Cell Therapy in Heart Failure - Minichart
BCDA Stock Jumps As FDA Clears Path For Helix Catheter - StocksToTrade
$BioCardia (BCDA.US)$ - Moomoo
BCDA Stock Holds Key Support As FDA Clears Paths For Helix - timothysykes.com
BioCardia stock surges on FDA trial pathway confirmation By Investing.com - Investing.com India
BioCardia stock surges on FDA trial pathway confirmation - Investing.com
BioCardia receives FDA feedback on heart failure trial pathway By Investing.com - Investing.com India
BioCardia receives FDA feedback on heart failure trial pathway - Investing.com
BioCardia® Receives FDA Minutes Confirming Eligibility for Premarket Approval of CardiAMP Cell Therapy for Ischemic Heart Failure - Quiver Quantitative
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF - The Manila Times
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
FDA minutes support BioCardia (NASDAQ: BCDA) CardiAMP HF II PMA pathway - Stock Titan
Biocardia Inc Stock (BCDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):